Navigation Links
First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer
Date:5/27/2008

Collaborative groups set out to confirm potential benefits of anticancer

therapies to treat women with breast cancer

PARIS, May 27 /PRNewswire/ -- A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin(R)) and the targeted therapy trastuzumab (Herceptin(R)), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

"Trastuzumab is already the standard of care across all stages of HER2-positive breast cancer and has a proven survival benefit. Bevacizumab has been shown to be of benefit when given in combination with chemotherapy for the treatment of metastatic breast cancer," said Dennis Slamon, MD, director of clinical/translational research at the University of California, Los Angeles' (UCLA) Jonsson Comprehensive Cancer Center and principal investigator, Cancer International Research Group. "The design of the BETH clinical trial is based on the preclinical and early clinical work from the Slamon/TRIO Laboratories at UCLA. We are looking forward to investigating the additional benefit to patients of combining these two treatments with chemotherapy in the treatment of early breast cancer."

"Despite treatment advances, over 400,000 women worldwide still die from breast cancer every year, so striving to improve treatment outcomes remains critical," said Norman Wolmark, MD, chairman of the Department of Human Oncology at the Allegheny General Hospital, and principal investigator, NSABP Foundation, Inc., Pittsburgh, Pennsylvania, USA, who welcomes the start of the study.

In BETH, patients will be randomized to a regimen of chemotherapy (either 6 cycles of docetaxel/carboplatin or 3 cycl
'/>"/>

SOURCE National Surgical Adjuvant Breast and Bowel Project
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... Laboratories, will move its laboratory operations in ... Raleigh Durham , North Carolina.  Sequenom ... performed at the North Carolina ...
(Date:5/27/2015)... , May 27, 2015 OpportunityAnalyzer: ... 2018 Summary GlobalData estimates that the ... market was approximately $179m across the 6MM covered ... are investing their attention, time, and financial resources ... of research and development (R&D) strategies. One notable ...
(Date:5/27/2015)... , May 27, 2015 Protein purification involves ... on differences in their physical properties. The objective of ... amount of functional protein with fewest contaminants. The global ... at a CAGR of around 5% to 6% during ... increased research in the pharmaceutical and biotechnological fields, growing ...
Breaking Medicine Technology:Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 2Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 3OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 2OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 3OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 4Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 2Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 3
... Phase III Study Provides Further Evidence of,the ... the Treatment,of Rheumatoid Arthritis, BASEL, Switzerland, June ... second multinational phase III Actemra,(tocilizumab) study, successfully ... greater proportion of patients treated with Actemra,in ...
... Production Through Inhibition,of PDE-4 Enzyme, PALO ALTO, ... a privately held pharmaceutical company, announced,today the ... of,AN2728, a first-in-class topical therapy under investigation ... AN2728 to be,well-tolerated, with activity comparable to ...
Cached Medicine Technology:New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 2New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 3New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 4Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis 2
(Date:5/28/2015)... Portland, Ore. (PRWEB) May 28, 2015 ... announced today that it has been named a “Cool ... titled Cool Vendors in Healthcare Payers, 2015 ... J. Lheureux. The report highlights innovative vendors, products and ... into new trends in the health care payer market. ...
(Date:5/28/2015)... Atlanta, GA (PRWEB) May 28, 2015 ... it will be breaking ground this summer on an ... , Focusing on resident engagement and connectivity in a ... a blend of innovative technology and southern hospitality to ... seniors. , The 93 unit community will feature luxuriously ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 JJ Mowder-Tinney, PT, ... of the New York Physical Therapy Association (NYPTA) by the ... an active member of the NYPTA. At the National ... the Neurology Section Research Committee and an abstract reviewer for ... she has been a member of the Program committee since ...
(Date:5/27/2015)... Gravity and volume loss in the ... Management Expert™, Holly CaSaroll, is excited to introduce a ... the mid face, without surgical intervention, and without downtime. ... a FDA approved procedure that can lift skin using ... is a new more lifting formula than its predecessor ...
(Date:5/27/2015)... 28, 2015 Calls Upon Individuals, Organizations and ... new nationwide initiative – a “Summer of Service” – seeks ... build partnerships to grow the number of individuals and organizations ... commitment to Veterans by inviting the community to visit and ... 29, 2015 from 1 – 3:00 p.m. in the auditorium. ...
Breaking Medicine News(10 mins):Health News:SpendWell Named a “Cool Vendor” by Gartner 2Health News:SpendWell Named a “Cool Vendor” by Gartner 3Health News:SpendWell Named a “Cool Vendor” by Gartner 4Health News:Thrive Announces Innovative New Senior Living Community in Huntsville, AL 2Health News:Skin Expert Holly CaSaroll Announces New Cutting Edge Results with RadiessePlus Filler Available at Detroit Skin and Wellness Clinic 2Health News:VA Begins “Summer of Service” to Bolster Volunteer Assistance for Veterans 2Health News:VA Begins “Summer of Service” to Bolster Volunteer Assistance for Veterans 3
... disorder is a serious and debilitating condition where individuals ... The episodes of low or elevated mood can last ... high. Antidepressants are commonly prescribed to ... not universally effective. Many patients still continue to experience ...
... , WEDNESDAY, May 30 (HealthDay News) -- ,The ancient medical ... a small new study suggests. Metabolic syndrome is a ... type of fat found in the blood), high fasting blood ... risk of diabetes and heart disease. Bloodletting was common ...
... information women receive about their future fertility following cancer diagnosis, ... BJOG: An International Journal of Obstetrics and Gynaecology . ... are increasing numbers of people of reproductive age undergoing such ... of Aberdeen and NHS Grampian - looks at perceptions and ...
... (HealthDay News) -- A popular European fitness routine called Nordic ... a small new study. In Nordic walking, people walk ... those in cross-country skiing. This fast-growing form of exercise in ... heart failure patients, quality of life and reduces their risk ...
... , TUESDAY, May 29 (HealthDay News) -- ,Adult survivors ... quality of life because of the long-term physical effects ... Researchers used data from the Childhood Cancer Survivor Study ... hair loss experienced by more than 14,000 adult survivors ...
... , TUESDAY, May 29 (HealthDay News) -- Healthy brain nerve ... intelligence later in life, according to a new study. ... older people with robust brain wiring (white matter, or nerve ... a sign of intelligence. The study of 420 people ...
Cached Medicine News:Health News:Ketamine improved bipolar depression within minutes 2Health News:Could Bloodletting Ease Heart Risks for the Obese? 2Health News:Men and women receive different fertility advice following cancer diagnosis 2Health News:Men and women receive different fertility advice following cancer diagnosis 3Health News:'Nordic Walking' a Winner for Heart Failure Patients, Study Says 2Health News:Emotional Woes May Last for Childhood Cancer Survivors 2Health News:Healthy Brain Connections Help Maintain Intellect in Old Age 2
Irrigating Capsulorhexis Cystotome. Formed angled tip, 27 g. Overall length 16 mm. 5/box....
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Retrobulbar Needle, 23 g. Atkinson style bevel. Overall length 38 mm. 5/box....
20 g MVR knife. Dimensions: 31.8 mm x 1.18 mm x 2.7 mm....
Medicine Products: